Aurobindo Pharma Ltd

{"amount":4}

{"maxBuyBackPrice":1475,"totalAggregatedAmount":800,"offerType":"Tender Offer"}

{"actualRevenue":86459000000,"estimateRevenue":84825000000,"revenueSurprise":1634000000,"revenueSurprisePercent":1.926318891836133,"actualEPS":16.8,"estimateEPS":15.8632134,"surprise":0.9367865999999996,"surprisePercent":5.905402495562466}

{"actualRevenue":82857000000,"estimateRevenue":82501000000,"revenueSurprise":356000000,"revenueSurprisePercent":0.4315099210918655,"actualEPS":14.61,"estimateEPS":15.636855,"surprise":-1.026855000000001,"surprisePercent":-6.566889569545801}

{"actualRevenue":88533400000,"estimateRevenue":89127000000,"revenueSurprise":-593600000,"revenueSurprisePercent":-0.6660159098814052,"actualEPS":15.86,"estimateEPS":16.7438814,"surprise":-0.8838813999999999,"surprisePercent":-5.278832182841429}

{"actualRevenue":78680000000,"estimateRevenue":83938000000,"revenueSurprise":-5258000000,"revenueSurprisePercent":-6.264147346851247,"actualEPS":14.2,"estimateEPS":17.055165,"surprise":-2.855165,"surprisePercent":-16.74076445463881}

{"description":"Aurobindo Pharma shares fell nearly 9% after weak US business and Q1 results that missed estimates, raising concerns over near-term earnings pressure.","url":"https://www.zeebiz.com/market-news/news-aurobindo-pharma-shares-fall-almost-9-amid-weak-us-business-and-below-estimate-q1-numbers-162767","sentiment":"Negative","domain":"Zee Business"}

{"description":"Aurobindo Pharma fell over 5% on May 22 after Q4 profit rose 2% to ₹920.84 crore, but EBITDA dropped 5% and margin shrank to 19.2%, missing estimates despite 5.6% revenue growth.","url":"https://www.cnbctv18.com/market/aurobindo-pharma-share-price-q4-result-reaction-fy27-margin-guidance-us-biz-formulations-revenue-ws-l-19911386.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"USFDA inspection found severe contamination and data-integrity failures at Aurobindo Pharma's manufacturing sites, citing lapses in environmental monitoring and control that threaten product safety and regulatory actions.","url":"https://www.ndtvprofit.com/markets/aurobindo-pharma-shares-fall-after-usfda-raises-quality-and-documentation-concerns-at-telangana-unit-11051990","sentiment":"Negative","domain":"NDTV Profit"}

{"description":"Aurobindo Pharma reported Q3 earnings on February 10, 2026, with revenue rising 8.4% YoY to ₹8,646 crore, surpassing estimates. Net profit was ₹909.8 crore, slightly below expectations. Strong growth in Europe (27% YoY) and a solid US performance contributed to the results. Shares rose 1.09% ahead of the announcement.","url":"https://www.cnbctv18.com/market/aurobindo-pharma-share-price-q3-revenue-beat-europe-drives-performance-ws-l-19846151.htm","sentiment":"Positive","domain":"CNBCTV18"}